News

Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion
Q1 2025 Management View CEO Richard Paulson announced that the Phase 3 SENTRY trial in JAKi-naïve myelofibrosis patients "has ...